Brazilians Oncologist Pediatricians Introduce An Unpublished Research In The Most Important Oncology World Congress
Brazilians Oncologist Pediatricians Introduce an Unpublished Research in the most important Oncology World Congress
The results prove higher Survival and Quality of life in Children with Terminal and Strange Tumor in Brain
Sao Paulo, June 9, 2015 – For the first time, Brazilian Oncologist Pediatricians introduced clinical data of Polaris research, which revealed unpublished benefits for children with a strange brain tumor, the glioma of bridge, such cancer that has no cure yet.
Considering the fatal consequences and aggressiveness of this sickness, the best news is that there are still alive patients after 2 years of the conclusion of such research.
The research was performed in the Brazilian population and evaluated if the nimotuzumabe drug, associated with traditional therapy (radiotherapy), would bring benefits to children recently diagnosed with the sickness. Nimotuzumabe is a monoclonal antibody that operates in the cell receptor (called EGFR) blocking its multiplication.
This research, with the support of Eurofarma, proved that this association increased the patients’ survival, but also, that the treatment was well tolerated, that is to say, without significant collateral effects, allowing quality of life to patients due to the impossibility of cure.
These and other clinical results of the investigation will be introduced in the American Oncology Congress (Asco), the most important Oncology World Congress to take place from the 29th of May to 2nd of June in Chicago, The United States of America.
“This research is of relevant importance for such devastating sickness. We are very happy with the results. A percentage of the population treated with this drug was benefitted and we are going to be able to share our results in such an important congress, the American Society of Clinical Oncology”, expresses Dr. Sidne Epelman, Director for the Pediatric Oncology Department of Santa Marcelina hospital, President of the Cancer Association for Children and Teenagers (TUCCA) and the foremost researcher of the Brazilian research.
Although uncommon (corresponds to approximately 10% of the brain tumors in Pediatrics, less than 200 cases per year), the diffuse intrinsic glioma of bridge, tumor of central nervous system in children is the one that represents the worst evolution, independent of the scientific community efforts. Most of the times, children survive more than 9 months after diagnosis.
Nimotuzumabe, as an example of the monoclonal antibodies works with less collateral effects in connection to the chemotherapeutics, due to, it is an objective therapy that works in a specific place, directly to the glioma.
Other researches of nimotuzumabe for different oncologic indications are in progress around the world, even in Brazil, such as for the Esophagus and Uterine Cervix cancer. Nowadays, nimotuzumabe is approved as an orphan drug for the treatment for children with a tumor in the central system, that do not responded well to the initial one (first election).
Eurofarma, apart from selling CIMAher with exclusivity – commercial name of nimotuzumabe – is the first company in the country in investing in researches like these, and the only national one that participates in the Nimotuzumab Global Development Consortium, consortium that gathers different companies around the world such as Oncoscience (Germany) and European Community), Daiichi Sakyo (Japan), Biocon (India), among others.
About Dr. Sidnei Epelman
Pediatric Oncologist for more than 30 years, he has a specialization in Pediatrics of A.C. Camargo Hospital. He performed some internship in prestigious pediatric oncology centers abroad, such as MD Anderson Cancer Center, Mayo Clinic, St Jude’s Research Cancer Hospital and National Cancer Institute.
He is the founder and president of the Children and Teenagers with Cancer Association (TUCCA). Nowadays he is the Director for the Pediatric Oncology Service at Santa Marcelina Hospital and coordinates cooperative groups for brain tumors treatment of the Brazilian Pediatric Oncology (SOBOPE). He is also the president, in Brazil, of the International Network for Cancer Treatment and Investigation (INCTR, in English) working in the coordination of pediatric oncology programs and palliative cares in the world for management of clinic research in oncology.
Besides having several award-winning works in Brazil and abroad, and have participated in dozens of congress, meetings and symposiums, he received for 2 years in-a-row the Analysis in Medicine Award and he is also jury of the Saúde/Health Prize by Abril Editors in health for children category.
Recently he published the book “Oncology in the Teenager”, the first work in Brazil related to treat cancer in adolescence.
About TUCCA
TUCCA (Children and Teenagers with Cancer Association) is a non-profit and non-governmental organization that offers an excellent multidisciplinary treatment for children and teenagers with cancer, without any cost to patient and family. During 16 years of work, we have served 2,400 patients, reaching cure rates of 80%, index until 60% up to the Brazilian average, matched only by the Europe and The United States of America ones.
To optimize resources, TUCCA, has a partnership with Santa Marcelina Hospital and applies the raised values, directly and exclusively, in which makes difference, to offer adequate treatment and get the best results. Besides the treatment, it works also in research, early diagnosis and training to professional, and it has a multidisciplinary team that helps patients and family until they feel absolutely well.
About Eurofarma
Eurofarma Group is the first multinational Brazilian pharmaceutical, with 100% national assets and 43-year-experience, accepted by medical community and society for promoting access to health and quality of life with treatments at fair price, quality and innovation.
Very well known in Brazil and abroad, it has a remarkable place working in the Medical Prescription, OTC, Generics, Hospitable, Tendering, Oncology, Third Party Services and Veterinary segments.
With a portfolio of more than 200 products and 200 million unities sold just in Brazil, it has presence in 15 countries, such as: Argentina, Belize, Bolivia, Chile, Colombia, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama, Peru, Dominican Republic and Uruguay.
Selected by GPTW as one of the best companies to work, it has 5,900 collaborators, being among them 2,200 sales representatives, being the biggest medical sales force of the country.
With an average growth of 18% in the last 12 years, reaching in year 2014 a revenue od R$2,6 billion and 6% of the liquid sales in research and development.
Help employers find you! Check out all the jobs and post your resume.
The results prove higher Survival and Quality of life in Children with Terminal and Strange Tumor in Brain
Sao Paulo, June 9, 2015 – For the first time, Brazilian Oncologist Pediatricians introduced clinical data of Polaris research, which revealed unpublished benefits for children with a strange brain tumor, the glioma of bridge, such cancer that has no cure yet.
Considering the fatal consequences and aggressiveness of this sickness, the best news is that there are still alive patients after 2 years of the conclusion of such research.
The research was performed in the Brazilian population and evaluated if the nimotuzumabe drug, associated with traditional therapy (radiotherapy), would bring benefits to children recently diagnosed with the sickness. Nimotuzumabe is a monoclonal antibody that operates in the cell receptor (called EGFR) blocking its multiplication.
This research, with the support of Eurofarma, proved that this association increased the patients’ survival, but also, that the treatment was well tolerated, that is to say, without significant collateral effects, allowing quality of life to patients due to the impossibility of cure.
These and other clinical results of the investigation will be introduced in the American Oncology Congress (Asco), the most important Oncology World Congress to take place from the 29th of May to 2nd of June in Chicago, The United States of America.
“This research is of relevant importance for such devastating sickness. We are very happy with the results. A percentage of the population treated with this drug was benefitted and we are going to be able to share our results in such an important congress, the American Society of Clinical Oncology”, expresses Dr. Sidne Epelman, Director for the Pediatric Oncology Department of Santa Marcelina hospital, President of the Cancer Association for Children and Teenagers (TUCCA) and the foremost researcher of the Brazilian research.
Although uncommon (corresponds to approximately 10% of the brain tumors in Pediatrics, less than 200 cases per year), the diffuse intrinsic glioma of bridge, tumor of central nervous system in children is the one that represents the worst evolution, independent of the scientific community efforts. Most of the times, children survive more than 9 months after diagnosis.
Nimotuzumabe, as an example of the monoclonal antibodies works with less collateral effects in connection to the chemotherapeutics, due to, it is an objective therapy that works in a specific place, directly to the glioma.
Other researches of nimotuzumabe for different oncologic indications are in progress around the world, even in Brazil, such as for the Esophagus and Uterine Cervix cancer. Nowadays, nimotuzumabe is approved as an orphan drug for the treatment for children with a tumor in the central system, that do not responded well to the initial one (first election).
Eurofarma, apart from selling CIMAher with exclusivity – commercial name of nimotuzumabe – is the first company in the country in investing in researches like these, and the only national one that participates in the Nimotuzumab Global Development Consortium, consortium that gathers different companies around the world such as Oncoscience (Germany) and European Community), Daiichi Sakyo (Japan), Biocon (India), among others.
About Dr. Sidnei Epelman
Pediatric Oncologist for more than 30 years, he has a specialization in Pediatrics of A.C. Camargo Hospital. He performed some internship in prestigious pediatric oncology centers abroad, such as MD Anderson Cancer Center, Mayo Clinic, St Jude’s Research Cancer Hospital and National Cancer Institute.
He is the founder and president of the Children and Teenagers with Cancer Association (TUCCA). Nowadays he is the Director for the Pediatric Oncology Service at Santa Marcelina Hospital and coordinates cooperative groups for brain tumors treatment of the Brazilian Pediatric Oncology (SOBOPE). He is also the president, in Brazil, of the International Network for Cancer Treatment and Investigation (INCTR, in English) working in the coordination of pediatric oncology programs and palliative cares in the world for management of clinic research in oncology.
Besides having several award-winning works in Brazil and abroad, and have participated in dozens of congress, meetings and symposiums, he received for 2 years in-a-row the Analysis in Medicine Award and he is also jury of the Saúde/Health Prize by Abril Editors in health for children category.
Recently he published the book “Oncology in the Teenager”, the first work in Brazil related to treat cancer in adolescence.
About TUCCA
TUCCA (Children and Teenagers with Cancer Association) is a non-profit and non-governmental organization that offers an excellent multidisciplinary treatment for children and teenagers with cancer, without any cost to patient and family. During 16 years of work, we have served 2,400 patients, reaching cure rates of 80%, index until 60% up to the Brazilian average, matched only by the Europe and The United States of America ones.
To optimize resources, TUCCA, has a partnership with Santa Marcelina Hospital and applies the raised values, directly and exclusively, in which makes difference, to offer adequate treatment and get the best results. Besides the treatment, it works also in research, early diagnosis and training to professional, and it has a multidisciplinary team that helps patients and family until they feel absolutely well.
About Eurofarma
Eurofarma Group is the first multinational Brazilian pharmaceutical, with 100% national assets and 43-year-experience, accepted by medical community and society for promoting access to health and quality of life with treatments at fair price, quality and innovation.
Very well known in Brazil and abroad, it has a remarkable place working in the Medical Prescription, OTC, Generics, Hospitable, Tendering, Oncology, Third Party Services and Veterinary segments.
With a portfolio of more than 200 products and 200 million unities sold just in Brazil, it has presence in 15 countries, such as: Argentina, Belize, Bolivia, Chile, Colombia, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama, Peru, Dominican Republic and Uruguay.
Selected by GPTW as one of the best companies to work, it has 5,900 collaborators, being among them 2,200 sales representatives, being the biggest medical sales force of the country.
With an average growth of 18% in the last 12 years, reaching in year 2014 a revenue od R$2,6 billion and 6% of the liquid sales in research and development.
Help employers find you! Check out all the jobs and post your resume.